TG Therapeutics soars as Cantor Fitzgerald sees sclerosis drug sales to beat estimates

TG Therapeutics

10/04/2023 20:52

** Shares of TG Therapeutics Inc  TGTX.O  rise 22.9% to
$19.03, among top pct. gainers across U.S. exchanges
    ** Brokerage Cantor Fitzgerald sees "solid jump" in March
sales for TGTX newly approved multiple sclerosis drug Briumvi
    ** Says co's drug is likely to meet or exceed the current Q1
2023 revenue estimates of $3.8 mln
    ** Notes the drug reported sales of $3.3 mln for March 2023,
 according to Symphony Health data; sales for February were
~$0.5 mln 
    ** Brokerage estimates Briumvi sales of more than $5 mln in
the first quarter vs $4 mln sales reported by Symphony for Q1
2023
    ** Investor focus during the initial period seems to be more
on the feedback from neurologists regarding Briumvi use, which,
based on recent physician checks, is very positive and bodes
well for the rest of the year - Cantor Fitzgerald
    ** Including session gains, stock up ~60% YTD

 (Reporting by Sriparna Roy)
 ((Sriparna.Roy@thomsonreuters.com;))